CXCL14 (C-X-C motif chemokine ligand 14) is a small secreted protein belonging to the chemokine family, primarily involved in immune cell recruitment, tissue homeostasis, and inflammatory responses. Unlike many chemokines, CXCL14 lacks a conserved ELR motif and exhibits broad expression in epithelial tissues, stromal cells, and immune cells, though its receptor remains controversial, with proposed candidates including GPR85. ACKR2. and atypical chemokine receptors. CXCL14 has been implicated in diverse physiological and pathological processes, including antimicrobial defense, angiogenesis regulation, and metabolic disorders, but its role in cancer is particularly complex, displaying both tumor-suppressive and pro-tumorigenic effects depending on context.
Antibodies against CXCL14 are essential tools for studying its expression patterns, signaling mechanisms, and functional roles. They enable detection of endogenous CXCL14 in tissues (via immunohistochemistry) or biological fluids (via ELISA/Western blot), localization studies, and receptor interaction analyses. Commercially available CXCL14 antibodies include monoclonal and polyclonal variants, often raised against specific epitopes (e.g., human CXCL14 amino acids 22-98). Validation remains critical due to CXCL14's low molecular weight (~10 kDa) and potential cross-reactivity with other chemokines. Recent studies using CXCL14 antibodies have revealed its dual role in cancers—acting as a tumor suppressor in breast and head/neck cancers by inhibiting angiogenesis, while promoting progression in pancreatic and prostate cancers through immune cell modulation. These antibodies also facilitate research into CXCL14's emerging functions in obesity-associated inflammation and antimicrobial peptide production.